Tales From The Road
This panel brings together biotech and medtech entrepreneurs to tell their stories of raising capital. You’ll hear their firsthand accounts of navigating the fundraising process and raising capital. Topics may include:
• What stumbling blocks had they hit?
• How had they solved the issues, and what had they learned about raising capital?
• How did they go about finding potential investors, and how did they determine which investors they should pursue?
The panel discusses what the early stage fundraising process was like for them and how others can build an outbound marketing campaign to raise money.
Greg Mannix, VP of International Business Development, Life Science Nation
Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to succesfully fundraise and to facilitate cross-boarder investments, licensing and M&A transactions.
Ryan Shelton, CEO, PhotoniCare
Ryan Shelton is CEO and founder of PhotoniCare, a medical device company revolutionizing diagnosis of common diseases at the front lines of healthcare. PhotoniCare’s first product is a handheld device that can see through the eardrum to enable physicians to make better decisions about antibiotic and surgical intervention. He has led the company as CEO since its inception, raising over $6M in dilutive and non-dilutive funding to advance the company’s objectives. Dr. Shelton received a PhD in Bioengineering from Texas A&M University in 2012. He has won multiple awards for entrepreneurial and technical achievement. Dr. Shelton is passionate about PhotoniCare’s current efforts improving the management of chronic middle ear infections in children, because of the frustrations he’s faced as a parent of his own children dealing with these chronic infections and hearing loss.
Tyler Wanke, CEO & Co-Founder, Innoblative Designs
Tyler Wanke is the CEO of Innoblative, a Chicago and Boston-based advanced energy device company innovating the treatment of early stage breast cancer. He co-invented the original Innoblative technology while in Medical school at Northwestern University, and since has raised over $3M for Innoblative, including National Science Foundation (NSF) grant funding. Innoblative is in final stages of product development and clinical trials. He also co-founded EDGe Surgical, an Orthopaedic and Spine MedTech company, and volunteers on a Board of Cures Within Reach (CWR), a non-profit dedicated to funding the re-purposing of existing drugs and devices to treat patients with limited other treatment options. He has an MBA from Northwestern’s Kellogg School of Management, a Masters of Engineering Management from Northwestern’s McCormick School of Engineering, and a BS in Neurobiology from University of Wisconsin – Madison.
Joyce Lonergan, CEO & Co-founder, Mellitus
Joyce Lonergan has over 25 years of experience in industry, venture capital and Wall Street with emerging healthcare companies. Ms. Lonergan previously served as a Managing Partner at SR One. Prior to that, Ms. Lonergan co-founded and served as Managing Director of Caxton Healthcare Venture Management, LLC. She previously served as Vice President of Corporate Development and Corporate Communications and Investor Relations at Chiron Corporation. Earlier in her career, Ms. Lonergan was a Biotechnology Equity Research Analyst at Cowen and Company. She also had previous investment and business development roles at Vector Fund Management and Repligen Corporation. Ms. Lonergan began her career in research at Tufts Medical Center. Ms. Lonergan holds a B.S. in biology from Emmanuel College and an MBA from the Simmons College Graduate School of Management
Prem Premsrirut, CEO, Mirimus
Dr. Premsrirut is co-founder of Mirimus, Inc., having established the business and team from the ground up following her scientific training. She is an expert in the development and use of RNAi transgenic mice for fast and flexible validation and toxicity assessment of candidate genes targets in vivo. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice and pioneered a novel approach for the generation of “speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer. She has pioneered methods for implementing CRISPR/Cas9 genome editing for the rapid creation of animal models. Dr. Premsrirut was an MD/PhD fellow at SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory. She received her Ph.D. in genetics and cancer biology following her training in the laboratory of Dr. Scott Lowe. Her work focused on the development of transgenic mouse models to study the effects of tumor maintenance on lung cancer using RNA interference. She received her M.D. from Stony Brook School of Medicine and Winthrop University Hospital with an emphasis on trauma surgery. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. Dr. Premsrirut is also an alumni of the Goldman Sachs 10KSB entrepreneurship program that provides business education for company growth and acceleration.